Related Experiment Videos
[Clinical studies on cefozopran in pediatrics]
H Morita1, M Fujieda, Y Morisawa
1Department of Pediatrics, Kochi Medical School.
The Japanese Journal of Antibiotics
|November 1, 1994
Summary
Cefozopran (CZOP), a new parenteral cephalosporin, demonstrated 100% clinical efficacy and bacterial eradication in pediatric infections. This new antibiotic shows promise for treating various childhood infections with minimal side effects.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Antimicrobial therapy
Background:
- Parenteral cephalosporins are crucial in treating pediatric infections.
- Cefozopran (CZOP) is a novel cephalosporin developed for parenteral administration.
- Evaluating new antimicrobial agents in pediatric populations is essential for expanding treatment options.
Purpose of the Study:
- To assess the clinical efficacy and safety of cefozopran (CZOP) in pediatric patients.
- To determine the bacterial eradication rates associated with CZOP treatment.
- To identify any adverse events or abnormal laboratory findings during CZOP therapy.
Main Methods:
- A clinical study involving 16 pediatric patients with various infections.
- CZOP administered intravenously at doses of 20-35 mg/kg body weight three times daily for 4-14 days.
- Clinical outcomes, bacterial eradication, and adverse events were monitored.
Main Results:
- 100% clinical efficacy rate (10 excellent, 6 good) across all treated pediatric patients.
- 100% bacterial eradication rate for identified pathogenic bacteria.
- One case of skin rash and transient elevations in liver enzymes (GPT/GOT) were observed in a few patients.
Conclusions:
- Cefozopran (CZOP) exhibits high clinical efficacy and excellent bacterial eradication in pediatric infections.
- The safety profile of CZOP appears favorable, with minor adverse events reported.
- CZOP represents a promising therapeutic option for managing bacterial infections in children.